左氧氟沙星联合头孢哌酮舒巴坦对老年肺炎的症状改善及炎症水平的影响

Objective To analyze the effect of levofloxacin plus cefoperazone sulbactam in the treatment of elderly patients with pneumonia, and to explore its effect on symptom improvement and inflammatory response. Methods We selected 80 elderly patients with pneumonia (community-acquired pneumonia) from October 2023 to October 2024. The patients were divided into control group (n=40) and observation group (n=40). The control group was treated with cefoperazone sulbactam, and the observation group was treated with levofloxacin combined with cefoperazone sulbactam. To compare the clinical efficacy, changes in symptoms (fever, cough, sputum, dyspnea, pulmonary rales), inflammatory markers ［C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6) ］, and adverse reactions between groups. Results Compared with the control group (82.50%), the observation group (97.50%) had a higher total effective rate of treatment (P＜0.05). Compared to the control group, the observation group had a shorter relief time for all symptoms (P＜0.05). There was no significant difference in the levels of inflammatory markers between the groups before treatment (P＞0.05). After treatment, the levels of CRP, PCT, and IL-6 in both groups decreased, and compared with the control group, the observation group had lower levels (P＜0.05). The difference in the incidence of adverse reactions between the two groups (10.00% vs. 15.00%) was not significant (P＞0.05). Conclusion Levofloxacin combined with cefoperazone sulbactam can be used in the treatment of pneumonia in the elderly. It can improve the clinical symptoms, improve the clinical treatment efficiency, alleviate the inflammatory state, and has a higher overall safety.